Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab
Indentifying Epigenetic Biomarkers From Peripheral Blood of Advanced Osteosarcoma Patients, Who Recieve Famitinib and Camrelizumab Based on hMe-Seal Technique
Drug Resistance to Famitinib and Camrelizumab